ASIA PACIFIC GLUCOSE MONITORING SYSTEM MARKET FORECAST 2019-2028

ASIA PACIFIC GLUCOSE MONITORING SYSTEM MARKET FORECAST 2019-2028

  • May 2020 •
  • 153 pages •
  • Report ID: 5893071 •
  • Format: PDF
KEY FINDINGS
The Asia Pacific glucose monitoring system CGMS market is estimated to reach a CAGR of 24.60% over the forecast period, and the SMBG market is anticipated to register a CAGR of 6.27% during the projected period of 2019-2028. One of the significant factors making the region a lucrative market for GMS is increasing healthcare expenditure.

MARKET INSIGHTS
The Asia Pacific glucose monitoring system market growth is further surveyed by segmenting the region into the Philippines, India, South Korea, Vietnam, Malaysia, Australia, Thailand, Japan, Indonesia, China, and the rest of Asia Pacific that includes Bhutan, Cambodia, Bangladesh, Maldives, and many other small countries.Indonesian healthcare system depends largely on private sources that are market and profit-oriented, and are responsible for 80% of total health expenditure.

The pharmaceutical industry in Indonesia is getting consolidated. In Malaysia, diabetes is a major public health concern, affecting 2.8 million adults above the age of 30. Malaysia has an efficient system of a two-tier healthcare system consisting of government and private healthcare services. Public health services are offered for the entire population in the country, though under-staffing and long waits make people opt for private services. Medical devices, like blood glucose and pressure monitors, are gaining popularity. In countries like the Philippines, diabetes is surging at an alarming rate, due to the sedentary lifestyle and increasing dependence on electronic gadgets. Diabetes is not covered comprehensively by national insurance, and private insurance companies offer limited coverage.
Thailand is witnessing an increasing occurrence of diabetes due to an unhealthy lifestyle, high obesity rates, and an aging society.The government has launched nationwide programs for health promotion and disease prevention.

UCS, a national insurance scheme covers 76% of the population.Vietnam has been facing the prevalence of diabetes for the last ten years, with one in every 20 adults suffering from diabetes.

The average diabetes-related expenditure per patient is more than the average monthly salary in Vietnam.In Cambodia and Bangladesh, there is a high prevalence of diabetes.

Type 2 diabetes cases are increasing in the Maldives.

COMPETITIVE INSIGHTS
Some of the leading companies in the market include, I-Sens Inc, Johnson and Johnson, Nemaura Medical Inc, Medtronic, Morepen Laboratories Ltd, etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Companies mentioned
1. ABBOTT
2. APEX BIOTECHNOLOGY CORPORATION
3. ARKRAY INC
4. ASCENSIA
5. B BRAUN MELSUNGEN AG
6. BECTON DICKINSON AND COMPANY
7. DEXCOM
8. GLYSENS INC
9. INSULET CORP
10. I-SENS INC
11. JOHNSON AND JOHNSON
12. MEDTRONIC
13. MOREPEN LABORATORIES LTD
14. NEMAURA MEDICAL INC
15. ROCHE DIAGNOSTICS
16. SENSEONICS INC
17. TANDEM DIABETES CARE
18. TERUMO
19. WOCKHARDT
20. YPSOMED